The prevention of contrast-induced nephropathy by minimising the contrast agent “confers significant economical benefit”
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:588 |
|---|---|
| Enthalten in: |
PharmacoEconomics & outcomes news - 588(2009), 1 vom: Okt., Seite 10-10 |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Chronic Kidney Disease |
| Anmerkungen: |
© Adis International Ltd 2009 |
|---|
| doi: |
10.2165/00151234-200905880-00026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2038031509 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2038031509 | ||
| 003 | DE-627 | ||
| 005 | 20230509192351.0 | ||
| 007 | tu | ||
| 008 | 200819s2009 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00151234-200905880-00026 |2 doi | |
| 035 | |a (DE-627)OLC2038031509 | ||
| 035 | |a (DE-He213)00151234-200905880-00026-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 245 | 1 | 0 | |a The prevention of contrast-induced nephropathy by minimising the contrast agent “confers significant economical benefit” |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Adis International Ltd 2009 | ||
| 650 | 4 | |a Public Health | |
| 650 | 4 | |a Health Outcome | |
| 650 | 4 | |a Chronic Kidney Disease | |
| 650 | 4 | |a Retrospective Study | |
| 650 | 4 | |a Kidney Disease | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d Springer International Publishing, 1996 |g 588(2009), 1 vom: Okt., Seite 10-10 |w (DE-627)193388901 |w (DE-600)1308910-9 |w (DE-576)435516213 |x 1173-5503 |7 nnns |
| 773 | 1 | 8 | |g volume:588 |g year:2009 |g number:1 |g month:10 |g pages:10-10 |
| 856 | 4 | 1 | |u https://doi.org/10.2165/00151234-200905880-00026 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 936 | b | k | |a 44.40 |q VZ |
| 951 | |a AR | ||
| 952 | |d 588 |j 2009 |e 1 |c 10 |h 10-10 | ||